Trial Profile
A Randomized, Crossover Phase 1 Study to Evaluate the Effects of Pevonedistat on the QTc Interval in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Mar 2023
Price :
$35
*
At a glance
- Drugs Pevonedistat (Primary) ; Carboplatin; Docetaxel; Paclitaxel
- Indications Solid tumours
- Focus Pharmacodynamics
- Sponsors Takeda Oncology
- 01 Mar 2023 Results (n=44) assessing the effect of pevonedistat, a neural precursor cell expressed, developmentally down-regulated protein 8 (NEDD8)-activating enzyme inhibitor, on the heart rate-corrected QT (QTc) interval in cancer patients, published in the Clinical Pharmacology in Drug Development.
- 22 Jun 2021 Status changed from active, no longer recruiting to completed.
- 15 Jun 2021 Planned End Date changed from 14 Jun 2021 to 21 Jun 2021.